Senior Director, Multiomics

Senior Director, Multiomics

Our mission is to make biology easier to engineer. Ginkgo is constructing, editing, and redesigning the living world in order to answer the globe's growing challenges in health, energy, food, materials, and more. Our bioengineers make use of an in-house automated foundry for designing and building new organisms.

Level (Sr. Director) will be set to match the successful candidate's experience.

Location:

Boston, MA (Seaport / HQ) Reporting to:
General Manager, Ginkgo Data points Focus:
Scientific Excellence, Commercial Strategy (P&L), Functional Genomics, Arrayed Perturbation Response Profiling & Multiomic Platform Expansion

Ginkgo Data points defines the category of the Bio × AI data provider. We work with top pharma, biotech, tech, and techbio companies, and we've built our reputation on high-quality, large-scale, reproducible data generated by automation rather than by hand. We're a fee-for-service partner — our customers own their data, and our incentives are aligned with theirs.

As our Senior Director of Multiomics, you will own the vision, execution, and commercial success of our Multiomics business, including the functional genomics engine behind our Perturbation Response Profiling and Specialized HTS offerings. This is a genuinely intrapreneurial role: you operate at the frontier of business and science, report to the GM of Data points, and lead a multidisciplinary team of scientists, automation engineers, and bioinformaticians with GS&A support.

Your primary goal is to scale our arrayed multiomic perturbation platform into the best in the industry, and to own the full P&L for the vertical. The near-term growth thesis is clear:

• Find new applications for DRUG-seq — safety first. Expand our high-throughput transcriptomic screening into new use cases, with safety and predictive toxicology chief among them.
• Turn perturbation data into AI fuel. Position our datasets as the training substrate for the next generation of AI/ML models, and shape data generation specifically to serve model training.
• Round out the readout menu. Extend beyond transcriptomics and imaging into proteomics, metabolomics, and additional NGS methods that complete a true multiomic offering.
• Build products the industry doesn't have yet. Add new offerings to the portfolio — arrayed whole-genome CRISPR knockouts paired with rich multiomic readouts among them — and the drug-discovery power that kind of capability unlocks.

The role is anchored in discovery-stage functional genomics, with real room to extend our multiomic work into translational and clinical biomarkers — population-scale and direct-to-consumer rather than regulated diagnostics. If that's the work that excites you most, there's a home for it here.

Key Responsibilities

Commercial & P&L Ownership:
Define the go-to-market strategy for Multiomics Data points. Identify market gaps, set pricing for our high-value / low-cost-per-datapoint model, and own revenue growth and operational efficiency across a customer base that spans large pharma, biotech, and government.

Technical Vision &

Roadmap:

Set the scientific direction across our arrayed perturbation platform and multiomic readouts — DRUG-seq (high-throughput transcriptomics), high-content imaging and Cell Painting (morphological profiling), and CRISPR-edit verification — across arrayed chemical, genetic (CRISPR KO / CRISPRi), and siRNA / ASO modalities. Drive the expansion agenda above: new DRUG-seq applications (especially safety), data purpose-built for AI/ML training, new readouts (proteomics, metabolomics, additional NGS), and new products such as arrayed whole-genome CRISPR knockouts.

Strategic Team Leadership:
Lead and mentor a multidisciplinary team of roughly 10–15. Because Data points runs a central operations matrix, day-to-day task assignment flows through shared ops structures; your job is to set direction, develop the team, and bridge the gap between industrialized wetlab automation and computational/AI interpretation. A practical understanding of wetlab methods — assay development, cell culture, perturbation delivery —…